Insect sting allergy and venom immunotherapy: a model and a mystery.

[1]  S. Spector,et al.  Stinging insect hypersensitivity , 2004 .

[2]  D. Golden,et al.  Outcomes of allergy to insect stings in children, with and without venom immunotherapy. , 2004, The New England journal of medicine.

[3]  R. Hamilton.  Diagnostic methods for insect sting allergy , 2004, Current opinion in allergy and clinical immunology.

[4]  S. Durham,et al.  Mechanisms of immunotherapy: IgG revisited , 2004, Current opinion in allergy and clinical immunology.

[5]  J. Schroeder,et al.  Osteopontin: A potential biomarker for successful allergen immunotherapy , 2004 .

[6]  D. Hoffman.  Fatal reactions to hymenoptera stings. , 2003, Allergy and asthma proceedings.

[7]  U. Müller.  Recombinant Hymenoptera venom allergens , 2002, Allergy.

[8]  Y. Cho,et al.  Prevalence of pachycondyla chinensis venom allergy in an ant-infested area in Korea. , 2002, The Journal of allergy and clinical immunology.

[9]  Gordon H Guyatt,et al.  Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. , 2002, The Journal of allergy and clinical immunology.

[10]  Andrea B Wenderoth,et al.  Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. , 2001, The Journal of allergy and clinical immunology.

[11]  W. Hemmer,et al.  Antibody binding to venom carbohydrates is a frequent cause for double positivity to honeybee and yellow jacket venom in patients with stinging-insect allergy. , 2001, The Journal of allergy and clinical immunology.

[12]  A. Kagey‐Sobotka,et al.  Recombinant Allergens with Reduced Allergenicity but Retaining Immunogenicity of the Natural Allergens: Hybrids of Yellow Jacket and Paper Wasp Venom Allergen Antigen 5s1 , 2001, The Journal of Immunology.

[13]  R. Confino‐Cohen,et al.  Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious. , 2001, The Journal of allergy and clinical immunology.

[14]  D. Golden,et al.  Insect sting allergy with negative venom skin test responses. , 2001, The Journal of allergy and clinical immunology.

[15]  Sabbah,et al.  Diagnosis of venom allergy by flow cytometry. Correlation with clinical history, skin tests, specific IgE, histamine and leukotriene C4 release , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  D. Golden,et al.  Survey of patients after discontinuing venom immunotherapy. , 2000, The Journal of allergy and clinical immunology.

[17]  C. Akdis,et al.  Role of interleukin 10 in specific immunotherapy. , 1998, The Journal of clinical investigation.

[18]  U. Müller,et al.  Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. , 1998, The Journal of allergy and clinical immunology.

[19]  D. Golden,et al.  Discontinuing venom immunotherapy: extended observations. , 1998, The Journal of allergy and clinical immunology.

[20]  D. Golden,et al.  Natural history of Hymenoptera venom sensitivity in adults. , 1997, The Journal of allergy and clinical immunology.

[21]  J. Burgers,et al.  Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge. , 1997, The Journal of allergy and clinical immunology.

[22]  A. Helbling,et al.  Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. , 1997, The Journal of allergy and clinical immunology.

[23]  J. Deighton,et al.  Bee venom immunotherapy induces a shift in cytokine responses from a TH‐2 to a TH‐1 dominant pattern: comparison of rush and conventional immunotherapy , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  M. Jutel,et al.  Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. , 1995, Journal of immunology.

[25]  J. Demain,et al.  The natural history of exposure to the imported fire ant (Solenopsis invicta). , 1995, The Journal of allergy and clinical immunology.

[26]  I. Bernstein,et al.  Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. , 1994, Annals of allergy.

[27]  V. Zwan,et al.  Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. , 1994, The Journal of allergy and clinical immunology.

[28]  J. H. Day,et al.  Risk assessment in determining systemic reactivity to honeybee stings in sting-threatened individuals. , 1994, The Journal of allergy and clinical immunology.

[29]  A. Dubois,et al.  Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity. , 1994, The Journal of allergy and clinical immunology.

[30]  R. Reisman,et al.  Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. , 1993, The Journal of allergy and clinical immunology.

[31]  D. Golden,et al.  Selection of Hymenoptera venoms for immunotherapy on the basis of patient's IgE antibody cross-reactivity. , 1993, The Journal of allergy and clinical immunology.

[32]  R. Reisman.  Intentional diagnostic insect sting challenges: a medical and ethical issue. , 1993, The Journal of allergy and clinical immunology.

[33]  D. Charpin,et al.  Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[34]  R. H. Hamilton,et al.  Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. , 1992, The Journal of allergy and clinical immunology.

[35]  T. Freeman,et al.  Imported fire ant immunotherapy: effectiveness of whole body extracts. , 1992, The Journal of allergy and clinical immunology.

[36]  A. Helbling,et al.  Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. , 1992, The Journal of allergy and clinical immunology.

[37]  A. Kagey‐Sobotka,et al.  Clinical and immunologic follow-up of patients who stop venom immunotherapy. , 1991, The Journal of allergy and clinical immunology.

[38]  A. Helbling,et al.  Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. , 1991, The Journal of allergy and clinical immunology.

[39]  M. Szklo,et al.  The value of immunotherapy with venom in children with allergy to insect stings. , 1990, The New England journal of medicine.

[40]  R. Lockey,et al.  The Hymenoptera venom study. III: Safety of venom immunotherapy. , 1990, The Journal of allergy and clinical immunology.

[41]  J. Bousquet,et al.  Evolution of sensitivity to Hymenoptera venom in 200 allergic patients followed for up to 3 years. , 1989, The Journal of allergy and clinical immunology.

[42]  M. Szklo,et al.  Epidemiology of insect venom sensitivity. , 1989, JAMA.

[43]  R. Reisman,et al.  Further observations of stopping venom immunotherapy: comparison of patients stopped because of a fall in serum venom-specific IgE to insignificant levels with patients stopped prematurely by self-choice. , 1989, The Journal of allergy and clinical immunology.

[44]  J. Forster,et al.  Discontinuation of bee venom immunotherapy in children and adolescents. , 1985, The Journal of pediatrics.

[45]  J. Georgitis,et al.  Natural history of large local reactions from stinging insects. , 1984, The Journal of allergy and clinical immunology.

[46]  B. Paull,et al.  Fire ant venom hypersensitivity. I. Comparison of fire ant venom and whole body extract in the diagnosis of fire ant allergy. , 1983, The Journal of allergy and clinical immunology.

[47]  M. Szklo,et al.  An epidemiologic study of insect allergy in children. I. Characteristics of the disease. , 1982, The Journal of pediatrics.

[48]  D. Golden,et al.  Treatment failures with whole-body extract therapy of insect sting allergy. , 1981, JAMA.

[49]  D. Golden,et al.  Dose dependence of Hymenoptera venom immunotherapy. , 1981, The Journal of allergy and clinical immunology.

[50]  P. L. Smith,et al.  Physiologic manifestations of human anaphylaxis. , 1980, The Journal of clinical investigation.

[51]  D. Golden,et al.  Regimens of Hymenoptera venom immunotherapy. , 1980, Annals of internal medicine.

[52]  L. Lichtenstein,et al.  Insect allergy: the state of the art. , 1979, The Journal of allergy and clinical immunology.

[53]  R. Jones,et al.  Rush venom immunotherapy program for honeybee sting sensitivity. , 1979, The Journal of allergy and clinical immunology.

[54]  L. Lichtenstein,et al.  Allergy to insect stings. IV. Diagnosis by radioallergosorbent test (R.A.S.T.). , 1978, Journal of immunology.

[55]  L. Lichtenstein,et al.  A controlled trial of immunotherapy in insect hypersensitivity. , 1978, The New England journal of medicine.

[56]  L. Lichtenstein,et al.  Diagnosis of allergy to stinging insects by skin testing with Hymenoptera venoms. , 1976, Annals of internal medicine.

[57]  L. Lichtenstein,et al.  A case for venom treatment in anaphylactic sensitivity to hymenoptera sting. , 1974, The New England journal of medicine.

[58]  J. H. Barnard.  Studies of 400 Hymenoptera sting deaths in the United States. , 1973, The Journal of allergy and clinical immunology.

[59]  H. Bernton,et al.  Allergy to the Hymenoptera. V. Clinical study of 400 patients. , 1970, Archives of internal medicine.

[60]  Loge Jp.  INSECT-STING ALLERGY: QUESTIONNAIRE STUDY OF 2,606 CASES. , 1965 .

[61]  Loveless Mh,et al.  Wasp venom allergy and immunity. , 1956 .

[62]  J. Ring,et al.  Use of CD63 expression as marker of in vitro basophil activation in identifying the culprit in insect venom allergy. , 2004, Journal of investigational allergology & clinical immunology.

[63]  D. Golden.  Patterns of anaphylaxis: acute and late phase features of allergic reactions. , 2004, Novartis Foundation symposium.

[64]  R. Heddle,et al.  Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania. , 2003, The Journal of allergy and clinical immunology.

[65]  D. Golden,et al.  The discontinuation of Hymenoptera venom immunotherapy. , 1998, The Journal of allergy and clinical immunology.

[66]  A. Dubois,et al.  Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. , 1997, The Journal of allergy and clinical immunology.

[67]  R. Reisman.  Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. , 1992, The Journal of allergy and clinical immunology.

[68]  U. Müller,et al.  Combined active and passive immunotherapy in honeybee-sting allergy. , 1986, The Journal of allergy and clinical immunology.

[69]  A. Kagey‐Sobotka,et al.  A prospective study of the natural history of large local reactions after Hymenoptera stings in children. , 1984, The Journal of pediatrics.

[70]  T. H. Coghlan,et al.  51 Fire ant venom hypersensitivity , 1983 .

[71]  J. Parker,et al.  Diagnostic and therapeutic importance of individual honeybee venom allergens , 1982 .

[72]  R. Lockey,et al.  Monograph on insect allergy. , 1981 .

[73]  W. Busse,et al.  A multicenter study on skin-test reactivity of human volunteers to venom as compared with whole body Hymenoptera antigens. , 1981, The Journal of allergy and clinical immunology.

[74]  L. Lichtenstein,et al.  Effects of passive antibody in bee venom anaphylaxis. , 1978, The Johns Hopkins medical journal.

[75]  L. Lichtenstein,et al.  Allergy to insect stings. I. Diagnosis of IgE-mediated hymenoptera sensitivity by venom-induced histamine release. , 1974, The Journal of allergy and clinical immunology.

[76]  R. L. Benson,et al.  Allergy in its relation to bee sting , 1930 .